Theoretical stack · Weight Loss & Body Composition

Tesofensine + CagriSema

Central monoamine + GLP-1 + amylin — the triple-mechanism stack

Low (combination) / Moderate-High (per-compound) · By Editorial Team at ModernPeptideScience · Last reviewed: May 2026

Theoretical educational discussion

This page summarizes a peptide combination as discussed in the research and user communities. It does not constitute medical advice, dosing recommendations, or instructions for personal use. Combination-specific human RCT evidence is generally absent for these stacks; per-compound evidence does not transfer additively to combinations.

Decisions about peptide therapy require an appropriately licensed clinician. We do not sell peptides.

At a glance

CagriSema (cagrilintide + semaglutide) covers peripheral GLP-1 satiety plus amylin signaling. Adding tesofensine layers in central monoamine appetite suppression. Three orthogonal mechanisms simultaneously — incretin, amylin, and central monoamine. Theoretically maximum-coverage weight loss; practically the largest side-effect surface in the weight-loss stack space.

Compounds in the stack

Each compound's role in the combination, with link to its full peptide page for the underlying research.

Tesofensine

Triple monoamine reuptake inhibitor — adds the central appetite suppression layer that incretin and amylin pathways don't directly address

Phase 2 evidence · Mexican-approved

CagriSema

Fixed-ratio combination of cagrilintide (long-acting amylin analog) and semaglutide (GLP-1 agonist); Phase 3 REDEFINE program. Covers peripheral GLP-1 and amylin pathways in one product.

Phase 3 investigational · Weekly SC

Mechanistic rationale

This stack extends the tesofensine + GLP-1 logic by replacing the GLP-1-only arm with CagriSema, which combines GLP-1 agonism (semaglutide) with amylin agonism (cagrilintide) in a fixed-ratio product. The result is three mechanistically distinct appetite-suppression and metabolic regulation pathways operating simultaneously:

Peripheral GLP-1 signaling (semaglutide arm of CagriSema) — gut-derived satiety, slowed gastric emptying, glucose-dependent insulin release.
Amylin signaling (cagrilintide arm of CagriSema) — satiety from pancreatic islet-derived amylin pathway, complementary to GLP-1 with different temporal patterns and partially-overlapping but distinct CNS effects.
Central monoamine signaling (tesofensine) — serotonin, norepinephrine, and dopamine elevation acting on hypothalamic and reward-circuit appetite drivers.

The mechanistic non-overlap is real — these three pathways involve different receptors, different cellular signaling cascades, and different anatomical sites of action. The combination logic is "maximum mechanistic coverage of the available appetite-pathway biology."

The CagriSema component is itself still in Phase 3 development (REDEFINE program from Novo Nordisk). Phase 2 data showed cagrilintide + semaglutide produces ~17% weight loss over 32 weeks vs ~10% on semaglutide alone — the amylin arm appears to add meaningful additional weight loss beyond GLP-1 monotherapy. Phase 3 data is expected to confirm or refine this signal.

Human and emerging evidence

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

Reported user experiences

The reports below are aggregated from research forums, podcasts, and user-community discussions. They are useful as hypothesis-generating signals but are not controlled clinical data — selection bias, placebo response, and underreporting of adverse effects all apply.

Given CagriSema's investigational status, community use patterns are still emerging. Reports tend to focus on:

Pre-trial users accessing compounded versions report similar GI side-effect profile to semaglutide alone, with possibly somewhat earlier appetite suppression.
Adding tesofensine to CagriSema produces stimulant-class effects on top of the GI-dominant CagriSema profile.
The combination is being framed as "maximum modern weight-loss pharmacology" — accepting that the evidence is thinnest at this combination level.
Users committed to the three-mechanism approach typically have tried lower-complexity protocols first.

The combination is sufficiently new and complex that community reports should be heavily discounted relative to per-compound evidence. The combination-specific signal is too small to characterize confidently.

Potential benefits and risks

Potential benefits

Three mechanistically orthogonal pathways (GLP-1, amylin, central monoamine)
Each component has reasonable individual evidence support
CagriSema Phase 2 evidence supports the GLP-1 + amylin combination meaningfully
Tesofensine adds the central pathway that incretin and amylin don't directly address
Potentially the deepest weight-loss potential of any current peptide-and-adjacent combination
Mechanistic logic is genuinely coherent at the pathway-coverage level

Potential risks

Largest side-effect surface in the weight-loss stack space — GI from CagriSema plus cardiovascular and CNS from tesofensine
No controlled evidence for the three-component combination
CagriSema itself is still investigational; combining an unapproved product with tesofensine adds regulatory and safety uncertainty
Cardiovascular monitoring more important than any single component
Tesofensine's serotonergic action interacts with serotonergic medications independently of the other arms
Cost is substantial when each component is included
Source-quality complications across all three compounds in grey-market channels
Cycling complexity — tesofensine's 8-on/4-off doesn't align with continuous-use GLP-1 and amylin therapy
Risk of overshooting useful weight loss into clinically problematic ranges

Open questions

Does adding tesofensine to CagriSema produce meaningfully greater weight loss than CagriSema alone?
What is the cardiovascular safety profile of the three-mechanism combination?
How does CagriSema interact with tesofensine pharmacologically vs additive effects only?
Is the side-effect burden of the three-mechanism combination tolerable for long-term use?
When CagriSema becomes commercially available, will the FDA labeling include any guidance on combination with central appetite suppressants?

The takeaway

This is the maximum-mechanism-coverage weight-loss stack. The three components address peripheral GLP-1 signaling, amylin signaling, and central monoamine pathways — covering most of the well-characterized appetite-regulating biology simultaneously. The combination is mechanistically defensible at the pathway level and represents what an aggressive multi-mechanism approach to weight loss looks like in 2026.

It also represents the largest side-effect surface and the thinnest evidence base of any combination on this site. CagriSema is still investigational. Tesofensine has limited regulatory approval. The combination has zero controlled-trial evidence. The cardiovascular monitoring requirements are real, and the GI plus stimulant-class combined side-effect profile is meaningful.

For users committed to maximum-aggressive weight loss intervention with full awareness of the evidence gaps and willing to actively monitor cardiovascular and metabolic parameters, this stack represents the upper bound of the current pharmacological space. For most users, simpler protocols — semaglutide or tirzepatide monotherapy, with our tesofensine + GLP-1 combination as a step-up alternative — produce most of the achievable benefit with less complexity and a more-defensible evidence position.

References

Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management. Lancet. 2021;397(10286):1736-1748. https://pubmed.ncbi.nlm.nih.gov/33894838/
Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet. 2008;372(9653):1906-1913. https://pubmed.ncbi.nlm.nih.gov/18950853/
Frias JP, et al. Cagrilintide co-administered with semaglutide in adults with overweight or obesity (Phase 2 REDEFINE precursor data). Diabetes Obes Metab. 2023. https://pubmed.ncbi.nlm.nih.gov/?term=cagrilintide+semaglutide+phase+2